Dong-A ST-Meju, Overseas Sales Collaboration for ECG Monitoring 'HiCardi'

Park Jeonghwan, CEO of Meju, and Kim Minyoung, CEO of Dong-A ST (from left), are taking a commemorative photo at the signing ceremony for the overseas licensing agreement of 'HiCardi'.
[Photo by Dong-A ST]

[Asia Economy Reporter Chunhee Lee] Dong-A ST announced on the 1st that it signed an overseas distribution rights contract for Meju's remote electrocardiogram monitoring platforms ‘HiCardi’, ‘HiCardi Plus’, and ‘Live Studio’ at its headquarters in Yongdu-dong, Dongdaemun-gu, Seoul on the 31st of last month.

Under this contract, Dong-A ST plans to supply Meju's products to overseas markets using its global distribution network. Currently, Dong-A ST exports canned Bacchus and beverages, biopharmaceuticals, and anti-tuberculosis drugs to about 40 countries in Europe, South America, Asia, and Africa. As of the third quarter of last year, exports accounted for 25.1% of total sales.

Meju is a digital healthcare company developing wearable electrocardiogram patches such as HiCardi and HiCardi Plus, and platforms like Live Studio that can monitor multiple patients in real time. HiCardi and HiCardi Plus are mobile biosignal monitoring systems that use wearable patches and smartphones to monitor multiple patients' electrocardiograms, heart rates, body surface temperatures, and respiration anytime and anywhere in real time. The lightweight wearable patch form resolves inconveniences experienced by patients and medical staff with conventional electrocardiogram devices. They have received Class II medical device approval from the Ministry of Food and Drug Safety and obtained the European CE certification complying with the Medical Devices Directive 93/42/EEC (MDD). Live Studio is software that monitors and records biosignal data on a computer for diagnosis and monitoring purposes.

In July last year, Dong-A ST signed a domestic distribution rights contract for HiCardi with Meju and has been conducting sales and marketing activities for HiCardi at tertiary general hospitals, general hospitals, and clinics. Through this, HiCardi is supplied to about 150 hospitals, including Seoul National University Hospital.

A Meju representative said, “We are very pleased to expand and strengthen our strategic partnership with Dong-A ST overseas. We will widely introduce our electrocardiogram remote monitoring platform technology to the global market and grow into a leading company in the digital healthcare market.” A Dong-A ST representative said, “We will actively pioneer the global market through Dong-A ST’s overseas distribution network and Meju’s competitive products. Starting with this contract, we will continue to supply innovative digital healthcare products to the global market and focus on nurturing the digital healthcare sector, which will be a future growth engine.”